|Bid||166.88 x 1300|
|Ask||167.01 x 1200|
|Day's range||166.08 - 170.67|
|52-week range||105.43 - 192.79|
|Beta (5Y monthly)||0.57|
|PE ratio (TTM)||N/A|
|Earnings date||26 Oct 2022 - 31 Oct 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||183.43|
BOTHELL, Wash., August 12, 2022--Seagen Inc. (Nasdaq: SGEN) today issued a statement regarding the outcome of the arbitration with Daiichi Sankyo Co. Ltd. ("Daiichi Sankyo") relating to the parties’ 2008 collaboration agreement for the use of Seagen’s antibody-drug conjugate (ADC) technology. The arbitrator ruled in favor of Daiichi Sankyo, citing statute of limitations and disagreement with Seagen on the interpretation of the contract.
From the FDA crackdown on Altria Group Inc.’s JUUL to RH’s recent decision to cut guidance due to a weak housing market outlook, experts can often make smart predictions about […]
Seattle Genetics (SGEN) delivered earnings and revenue surprises of 10.98% and 12.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?